Table 3 Adjusted hazard ratios for overall survival by RCC subtypes in the entire cohort; metastasis-naive and metastatic patients (adjusted for TNM stage).

From: Comparative analysis of oncologic outcomes in surgically treated patients with renal cell carcinoma and renal vein thrombosis by pathologic subtypes

Entire cohort (n = 604)

 

OS

HR

95% CI

p-value

Pathologic subtypes

Clear cell

RCC (n = 504)

Reference

 

Papillary RCC (n = 44)

1.023

0.639–1.636

0.925

 

Chromophobe RCC (n = 17)

1.411

0.720–2.766

0.315

 

Rare RCC (n = 39)

2.196

1.418–3.402

 < 0.001

Pathologic

T stage

pT3a (n = 359)

Reference

 

pT3b (n = 172)

1.224

0.931–1.610

0.147

 

pT3c (n = 28)

1.580

0.824–3.028

0.168

 

pT4 (n = 45)

1.949

1.286–2.953

0.002

Pathologic

N stage

pN0 (n = 163)

Reference

 

pN1 (n = 92)

1.398

0.952–2.053

0.087

 

pNx (n = 349)

0.850

0.633–1.142

0.282

Pathologic

M stage

pM0 (n = 447)

Reference

 

pM1 (n = 101)

2.560

1.853–3.538

 < 0.001

 

pMx (n = 56)

2.249

1.547–3.269

 < 0.001

  1. RCC, renal cell carcinoma; OS, overall survival; HR, hazard ratio; CI, confidence interval (95%).
Back to article page